Note one
The dose on the label and the dose in the capsule
The single most common question we get is whether the number on the jar is real. It is a fair question, and the honest answer is that nobody has published enough data to say for certain across the whole market. That is most of why we exist.
Here is what makes label accuracy hard even for a brand acting in good faith. Psilocybin content varies between mushrooms, between flushes from the same grow, and between parts of the same mushroom. A producer working from dried material has to homogenise it thoroughly before it goes anywhere near a capsule, and homogenising properly at small scale is genuinely difficult and unglamorous work. Skip it and you get a jar where the first capsule and the last capsule are meaningfully different products.
This is why we test several units from the same lot rather than one. An average that looks correct can hide a spread that matters enormously to the person taking it. If you are microdosing, a capsule that is quietly triple strength is not a bonus, it is your afternoon gone.
What you can do without waiting for us. Look for a brand that publishes lot numbers, because a lot number means somebody is tracking batches and can trace a problem. Look for testing the brand did not commission itself. And treat any product with no batch identifier at all as an unknown, however good the packaging looks.
Note two
A field guide to trusting this field
Psilocybin sits in an awkward place. It is regulated enough to be risky to talk about openly and unregulated enough that nobody is checking what gets sold. That combination attracts careful operators and careless ones in roughly equal numbers, and from the outside they can look identical, because both have nice websites.
A few things separate them in practice.
- Specificity. Careful brands tell you the species, the dose, and the batch. Careless ones tell you how the product will make you feel.
- Testing they did not pay to look good. Any brand can commission a certificate. Fewer will submit to testing they do not control.
- Willingness to publish a bad result. This is the strongest signal there is, and it is rare.
- Claims that stay inside what is known. A brand promising to fix your anxiety is telling you it does not care what the evidence says.
None of that requires a lab. It just requires reading the packaging like somebody is trying to sell you something, which they are.
Note three
Psychedelic optimism, meet peer review
There is real clinical research on psilocybin, and some of it is genuinely promising, particularly in supervised settings for depression that has not responded to other treatment. There is much less good evidence for the thing most people on this site are actually doing, which is taking small amounts regularly, on their own, without supervision.
Those are not the same subject, and the gap between them gets papered over constantly in marketing copy. A trial of a large supervised dose given alongside therapy tells you very little about a 125mg capsule taken on a Tuesday before work.
We are not saying microdosing does nothing. We are saying the published evidence is thin, the placebo effect in this area is unusually strong and well documented, and anyone telling you the science is settled has not read it. We would rather hand you an honest picture of what is known and let you decide than sell you certainty that does not exist.
What we can contribute is narrower and more useful. Whatever you decide to take, you should be able to know what is in it.
